In the opaque, high-stakes world of American healthcare, two words are becoming increasingly synonymous with reform: "choice" and "transparency." For decades, the pharmaceutical supply chain—a labyrinthine network of manufacturers, pharmacy benefit managers (PBMs), insurers, and providers—has operated under a system of misaligned incentives. This system has long been criticized for inflating costs, obscuring pricing, and limiting patient agency.
Recently, at Bullseye, an exclusive, invitation-only forum for healthcare investors and corporate leaders hosted by MedCity News in Chicago, industry heavyweights gathered to dissect these systemic failures. The panel discussion, featuring voices from Amazon Pharmacy, innovative PBM startups, and risk-management experts, offered a blistering critique of the status quo and a roadmap for a more consumer-centric future.
The Core Conflict: Why Formulary Access Hurts the Consumer
At the heart of the current pricing crisis is the "formulary"—a list of prescription medications covered by a health insurance plan. While intended to provide structure, critics argue that the formulary has morphed into an anti-competitive tool that restricts patient access and protects profit margins at the expense of clinical outcomes.
Tanvi Patel, General Manager of Amazon Pharmacy, did not mince words when describing the industry’s reliance on these restrictive lists. "Choice becomes paramount, and formulary is anti-choice," Patel stated. She argued that the current model creates a perverse incentive structure for pharmaceutical brand managers. By securing a dominant position on a formulary, a company can ensure its product is the default choice for patients, regardless of whether a more cost-effective or clinically superior alternative exists.
"You won’t abandon a model that is helping your own personal P&L or your own personal goals," Patel noted. She contrasted this with Amazon’s approach, which seeks to build a transparent marketplace. By listing both Amazon’s own products alongside third-party alternatives, the company aims to move away from the "one-choice-only" paradigm that has defined traditional pharmacy benefit management.
Chronology of the Debate: From Rebates to Reform
The current push for transparency did not emerge in a vacuum. It is the culmination of years of mounting frustration from patients, employers, and policymakers.
- Pre-2010s: The PBM model solidified its role as a middleman, with "gross-to-net" bubbles—the gap between the list price of a drug and the actual price paid by the insurer—growing significantly due to opaque rebate structures.
- 2015–2020: Public outcry over skyrocketing costs for life-saving drugs (such as insulin and EpiPens) forced Congress to hold multiple hearings. These sessions began to expose the "rebate trap," where PBMs negotiate discounts that are often not passed down to the consumer.
- 2021–2023: The rise of "disruptor" pharmacies, such as Amazon Pharmacy and Mark Cuban Cost Plus Drug Company, introduced direct-to-consumer models that prioritize pricing transparency.
- 2024: Industry events like Bullseye have shifted from discussing if the system should change to how the industry can dismantle the existing formulary-dependent incentives.
AJ Loiacono, CEO of Judi Health, a tech-enabled PBM, emphasized that the blame for these high prices cannot be placed solely on pharma companies. While pharma sets the list price, the PBM-led formulary system dictates the market access that keeps those prices high.
"I think if pharma was brave enough, they could do it, but they need to abandon the model of formulary access," Loiacono explained. He noted that in surveys of brand managers, the vast majority believe they are "winning" under the current strategy. Until that percentage drops below 50%, he argued, executives will be unwilling to report to their CFOs that they are abandoning a lucrative—albeit exploitative—business model.
The Anatomy of the Medical Benefit "Battle"
While the pharmacy benefit side (drugs picked up at a retail store) is undergoing intense scrutiny, the "medical benefit" side—drugs administered by a provider, such as oncology infusions or gene therapies—presents a far more complex challenge.
Annie Collins, Chief Commercial Officer at Aradigm Health, highlighted that when patients visit a clinic or hospital for treatment, they are effectively removed from the decision-making process. "You can pick your doctor, but from there, it’s mostly providers and payers having a battle in the background," she said.
The Three Arenas of Conflict
Collins identified three specific areas where this hidden battle drives up costs:
- Provider Markup: In some cases, doctors purchase medications from payers and add a markup to the price, effectively creating a financial "upside" for the provider in the treatment process.
- White Bagging: This occurs when payers force the use of a specific specialty pharmacy integrated into their own supply chain. The payer gains a financial benefit, but the process adds layers of logistical complexity that can delay patient care.
- Site-of-Care Disputes: Insurers and providers often clash over where a drug should be administered—the hospital or the home. These disputes are rarely about what is best for the patient; they are almost exclusively about which party can capture the highest margin from the facility fee.
Supporting Data: When Choice Fails
The consequences of these systemic inefficiencies are not merely theoretical; they are life-altering. Collins pointed to the emergence of breakthrough cell and gene therapies as a prime example of where the system is failing to serve the patient.
For sickle cell disease, two high-cost therapies are currently available: Casgevy (Vertex Pharmaceuticals) and Lyfgenia (Genetix Biotherapeutics). Clinical data suggests that Casgevy is safer and more efficacious. Furthermore, it is priced significantly lower than its competitor.
"You would be surprised how much people are still choosing Lyfgenia over Casgevy," Collins remarked. She attributed this not to clinical superiority, but to physician habits and existing relationships built during clinical trials. When the patient is blinded to these incentives and pricing structures, they lose the ability to advocate for the therapy that is both safer and more affordable.
Implications: A Path Toward Transparency?
The implications of these revelations are profound. If the industry continues to prioritize formulary rebates over patient outcomes, the result will be a continued erosion of public trust and inevitable, heavy-handed government intervention.
1. The Death of the "Gross-to-Net" Bubble
As platforms like Amazon and transparent PBMs gain market share, the traditional PBM model—which relies on the obfuscation of rebates—will likely face a liquidity crisis. If payers and employers move toward "pass-through" models where 100% of rebates are returned to the client, the incentive to prioritize high-cost drugs will vanish.
2. Empowering the Consumer
Patel’s assertion that "choice is paramount" is the rallying cry for a new generation of healthcare startups. By providing real-time pricing and clear therapeutic alternatives, these companies hope to turn the patient from a passive recipient of care into an informed consumer. The goal is to ensure that when a patient is told a drug isn’t covered, they are immediately presented with the "therapeutic alternative" rather than being handed a prohibitive cash price.
3. Regulatory Pressure
The Bullseye panel made it clear that the industry is aware of its own systemic flaws. However, whether the industry can reform itself from within remains a subject of intense debate. The pressure from Washington, D.C., is only mounting, and if private-sector leaders do not move toward a more transparent, choice-based model, they may soon find that the decision is taken out of their hands by federal regulators.
Conclusion: The Road Ahead
The consensus among the experts at Bullseye was clear: the American healthcare system is operating in a state of "managed ignorance." Patients are kept in the dark about why certain drugs are chosen, while stakeholders hide behind the complexity of formularies and medical benefits to protect their financial interests.
True change will require more than just technological fixes; it will require a fundamental shift in the culture of pharmaceutical brand management and provider compensation. As Amazon’s Tanvi Patel concluded, "If you start with the consumer and you don’t say, ‘I’m going to give you one choice and one choice only,’ that is when you are actually incentivized to do right by the patient."
The industry is at a crossroads. One path leads toward continued stagnation and deepening public resentment; the other, toward a transparent, competitive marketplace that finally puts the consumer at the center of the equation. Whether the industry has the "bravery"—as AJ Loiacono put it—to abandon the model that has served them so well for so long will determine the future of American healthcare.
